NASDAQ:PBYI - Puma Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.50
  • Forecasted Upside: 16.40 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.88
▼ -0.33 (-3.23%)
1 month | 3 months | 12 months
Get New Puma Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBYI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBYI

Average Price Target: $11.50
▲ +16.40% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Puma Biotechnology in the last 3 months. The average price target is $11.50, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 16.40% upside from the last price of $9.88.

Hold

The current consensus among 4 contributing investment analysts is to hold stock in Puma Biotechnology. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 4 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2021HC WainwrightReiterated RatingBuy$15.00High
8/10/2020CitigroupLower Price TargetNeutral$14.00 ➝ $12.00Medium
8/7/2020SVB LeerinkLower Price TargetMarket Perform$14.00 ➝ $10.00High
6/25/2020Bank of AmericaInitiated CoverageUnderperform$9.00High
5/20/2020Cantor FitzgeraldBoost Price TargetNeutral$14.00 ➝ $16.00High
5/15/2020SVB LeerinkReiterated RatingMarket PerformHigh
5/10/2020Royal Bank of CanadaReiterated RatingHold$13.00High
5/1/2020HC WainwrightReiterated RatingBuy$15.00High
4/20/2020Royal Bank of CanadaReiterated RatingHold$13.00High
2/28/2020CowenReiterated RatingHold$17.00High
2/26/2020HC WainwrightReiterated RatingBuy$15.00High
2/4/2020SVB LeerinkReiterated RatingMarket PerformHigh
1/27/2020Royal Bank of CanadaReiterated RatingHold$13.00Low
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
12/12/2019HC WainwrightReiterated RatingBuy$15.00Medium
12/6/2019HC WainwrightInitiated CoverageBuy$15.00Medium
11/8/2019Cantor FitzgeraldLower Price TargetNeutral$20.00 ➝ $14.00High
11/7/2019BarclaysLower Price TargetUnderweight$9.00 ➝ $6.00High
11/7/2019Royal Bank of CanadaLower Price TargetSector Perform$13.00High
10/8/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$24.00 ➝ $8.00High
8/12/2019CitigroupSet Price TargetHold$13.00High
8/12/2019JPMorgan Chase & Co.Reiterated RatingSell$13.00Medium
8/9/2019CowenReiterated RatingHold$25.00Low
8/9/2019BarclaysLower Price TargetUnderweight$21.00 ➝ $9.00High
7/5/2019CowenReiterated RatingHold$28.00High
6/5/2019CowenSet Price TargetHold$27.00Medium
5/29/2019The Goldman Sachs GroupLower Price TargetNeutral$29.00 ➝ $24.00Low
5/10/2019JPMorgan Chase & Co.Lower Price TargetUnderweight$27.00 ➝ $19.00High
5/10/2019CitigroupDowngradeBuy ➝ Neutral$24.00High
5/10/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00 ➝ $20.00High
4/1/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
3/3/2019JPMorgan Chase & Co.Reiterated RatingSell$27.00Medium
3/1/2019CowenReiterated RatingHold$68.00Low
3/1/2019CitigroupBoost Price TargetBuy ➝ Buy$67.00 ➝ $70.00Medium
2/28/2019Cantor FitzgeraldReiterated RatingBuy$57.00High
1/17/2019SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$21.00Low
1/3/2019GuggenheimDowngradeBuy ➝ NeutralHigh
12/18/2018Royal Bank of CanadaBoost Price TargetPositive ➝ Sector Perform$29.00Low
12/18/2018Cantor FitzgeraldBoost Price Target$55.00High
12/6/2018Royal Bank of CanadaBoost Price TargetSector Perform$26.00Low
11/19/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$36.00 ➝ $28.00Medium
11/2/2018Bank of AmericaDowngradeBuy ➝ UnderperformHigh
11/2/2018BarclaysDowngradeEqual Weight ➝ Underweight$72.00 ➝ $29.00High
11/2/2018CowenSet Price TargetHold$68.00High
11/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$83.00 ➝ $23.00High
11/2/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$75.00 ➝ $50.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$75.00Low
9/18/2018CitigroupLower Price TargetBuy$164.00 ➝ $151.00Medium
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$42.00High
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Buy$80.00 ➝ $83.00High
8/10/2018CowenReiterated RatingHold$80.00High
6/28/2018CitigroupBoost Price TargetBuy ➝ Buy$146.00 ➝ $164.00Low
5/11/2018Stifel NicolausLower Price TargetBuy ➝ Buy$95.00 ➝ $87.00Medium
5/7/2018Credit Suisse GroupSet Price TargetBuy$106.00Medium
4/26/2018Credit Suisse GroupSet Price TargetBuy$106.00High
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$90.00High
3/9/2018Stifel NicolausSet Price TargetBuy ➝ Buy$85.00 ➝ $95.00Low
3/2/2018Credit Suisse GroupSet Price TargetBuy$106.00High
3/2/2018BarclaysLower Price TargetOverweight ➝ Overweight$92.00 ➝ $90.00High
1/24/2018Bank of AmericaLower Price TargetBuy ➝ Buy$135.00 ➝ $115.00High
1/24/2018CitigroupLower Price TargetBuy ➝ Buy$164.00 ➝ $146.00High
1/24/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$147.00 ➝ $106.00High
1/24/2018Royal Bank of CanadaLower Price TargetSector Perform$77.00High
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Buy$138.00 ➝ $91.00High
1/24/2018CowenDowngradeOutperform ➝ Market Perform$123.00 ➝ $68.00High
1/22/2018Credit Suisse GroupSet Price TargetBuy$142.00 ➝ $147.00Low
1/15/2018Credit Suisse GroupSet Price TargetBuy$142.00High
1/3/2018CitigroupReiterated RatingBuy$164.00Low
11/10/2017Credit Suisse GroupBoost Price TargetOutperform$136.00 ➝ $142.00N/A
11/10/2017BarclaysReiterated RatingBuy$103.00 ➝ $122.00N/A
11/10/2017CitigroupBoost Price TargetBuy ➝ Buy$156.00 ➝ $164.00N/A
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform$108.00 ➝ $92.00N/A
10/27/2017SVB LeerinkBoost Price TargetPositive ➝ Outperform$140.00N/A
10/9/2017Bank of AmericaReiterated RatingBuy$117.00 ➝ $135.00N/A
10/5/2017CitigroupReiterated RatingBuy$114.00 ➝ $156.00N/A
10/4/2017JPMorgan Chase & Co.Reiterated RatingBuy$131.00High
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 ➝ $130.00Low
9/27/2017Credit Suisse GroupReiterated RatingOutperform$136.00High
9/11/2017Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$118.00 ➝ $136.00Medium
9/6/2017BarclaysInitiated CoverageOverweight$103.00High
8/10/2017Stifel NicolausReiterated RatingBuy$118.00 ➝ $110.00High
8/9/2017JPMorgan Chase & Co.Set Price TargetBuy$105.00High
8/2/2017SVB LeerinkReiterated RatingOutperform$125.00Low
8/1/2017JPMorgan Chase & Co.Reiterated RatingBuyHigh
7/22/2017CowenReiterated RatingOutperform$91.00 ➝ $120.00Medium
7/21/2017Bank of AmericaReiterated RatingBuy$100.00 ➝ $117.00Low
7/19/2017SVB LeerinkReiterated RatingOutperform$115.00 ➝ $125.00Medium
7/18/2017JPMorgan Chase & Co.Reiterated RatingBuyMedium
7/18/2017CitigroupReiterated RatingBuy$114.00Medium
7/18/2017Stifel NicolausReiterated RatingBuy$105.00 ➝ $118.00Medium
7/18/2017Credit Suisse GroupReiterated RatingOutperform$90.00 ➝ $118.00High
7/17/2017Royal Bank of CanadaSet Price TargetHold$88.00Medium
7/10/2017Stifel NicolausReiterated RatingBuy$105.00Medium
7/10/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$115.00Medium
6/30/2017CitigroupReiterated RatingBuy$105.00Low
6/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$89.00Medium
6/6/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$60.00 ➝ $88.00Low
6/5/2017Stifel NicolausReiterated RatingBuy$105.00Low
5/28/2017CitigroupUpgradeBuy$105.00Low
5/25/2017Credit Suisse GroupBoost Price TargetOutperform$58.00 ➝ $90.00Low
5/25/2017CowenUpgradeNeutral ➝ Outperform$91.00Low
5/25/2017Bank of AmericaBoost Price TargetBuy$72.00 ➝ $86.00Low
5/25/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $60.00Low
5/24/2017JPMorgan Chase & Co.Reiterated RatingOverweight$89.00Medium
5/22/2017Credit Suisse GroupSet Price TargetBuy$58.00High
5/22/2017CowenReiterated RatingMarket Perform ➝ Market PerformHigh
5/22/2017CitigroupReiterated RatingBuy$88.00High
5/22/2017Stifel NicolausReiterated RatingBuy$88.00High
5/10/2017Royal Bank of CanadaSet Price TargetHold$40.00Low
4/19/2017Stifel NicolausReiterated RatingBuy$88.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$58.00High
3/4/2017CitigroupReiterated RatingBuy$88.00N/A
3/3/2017Royal Bank of CanadaReiterated RatingSector Perform$57.00 ➝ $48.00N/A
3/2/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$48.00 ➝ $17.00N/A
3/2/2017Royal Bank of CanadaLower Price TargetSector Perform$48.00 ➝ $17.00N/A
1/18/2017Credit Suisse GroupReiterated RatingOutperformN/A
1/3/2017CitigroupSet Price TargetBuy$88.00N/A
11/30/2016Stifel NicolausReiterated RatingBuy$88.00N/A
11/16/2016Royal Bank of CanadaReiterated RatingSector PerformN/A
11/15/2016CowenReiterated RatingMarket PerformN/A
11/15/2016Credit Suisse GroupReiterated RatingOutperform$111.00N/A
11/14/2016JPMorgan Chase & Co.Set Price TargetBuy$89.00N/A
11/14/2016CitigroupSet Price TargetBuy$88.00N/A
11/10/2016Stifel NicolausReiterated RatingBuy$88.00N/A
9/22/2016Royal Bank of CanadaReiterated RatingSector PerformN/A
9/22/2016Credit Suisse GroupBoost Price TargetOutperform$54.00 ➝ $111.00N/A
9/21/2016Stifel NicolausUpgradeHold ➝ Buy$61.00 ➝ $88.00N/A
9/20/2016JPMorgan Chase & Co.Set Price TargetBuy$89.00N/A
9/20/2016CitigroupSet Price TargetBuy$88.00N/A
7/24/2016Royal Bank of CanadaReiterated RatingSector Perform$36.00 ➝ $46.00N/A
7/24/2016Stifel NicolausReiterated RatingHoldN/A
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
Puma Biotechnology logo
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $9.88
Low: $9.76
High: $10.23

50 Day Range

MA: $10.30
Low: $9.25
High: $11.60

52 Week Range

Now: $9.88
Low: $7.48
High: $14.14

Volume

1,645,200 shs

Average Volume

345,947 shs

Market Capitalization

$398.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Puma Biotechnology?

The following equities research analysts have issued stock ratings on Puma Biotechnology in the last twelve months: Bank of America Co., Citigroup Inc., HC Wainwright, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for PBYI.

What is the current price target for Puma Biotechnology?

4 Wall Street analysts have set twelve-month price targets for Puma Biotechnology in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 16.4%. HC Wainwright has the highest price target set, predicting PBYI will reach $15.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $9.00 for Puma Biotechnology in the next year.
View the latest price targets for PBYI.

What is the current consensus analyst rating for Puma Biotechnology?

Puma Biotechnology currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PBYI, but not buy more shares or sell existing shares.
View the latest ratings for PBYI.

What other companies compete with Puma Biotechnology?

How do I contact Puma Biotechnology's investor relations team?

Puma Biotechnology's physical mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company's listed phone number is 424-248-6500 and its investor relations email address is [email protected] The official website for Puma Biotechnology is www.pumabiotechnology.com.